echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Nuocheng Medical and Xijing Hospital develop an innovative treatment plan for hypertrophic cardiomyopathy

    Nuocheng Medical and Xijing Hospital develop an innovative treatment plan for hypertrophic cardiomyopathy

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hangzhou, October 12, 2021/PRNewswire/ - Citing innovative treatment strategies, the world’s first innovative treatment plan-Liwen RF™ radiofrequency ablation system developed by Nuocheng Medical and Professor Liu Liwen of Xijing Hospital to bring patients with hypertrophic cardiomyopathy Come to the gospel


    Current status of treatment of hypertrophic cardiomyopathy

    Hypertrophic cardiomyopathy (hereinafter referred to as "hypertrophic heart disease") is the most common inherited cardiovascular disease.


    At present, the treatment of obese heart disease mainly includes drug therapy, alcohol ablation of the ventricular septum, and surgical (rotary septal resection)


    Combination of medicine and industry, Nuocheng Medical's leading layout

    Adhering to the concept of technological innovation to solve international clinical pain points, Nuocheng Medical and Professor Liu Liwen from Xijing Hospital brought together a team of clinical experts and engineers to successfully develop the world's first product that applies radio frequency to treat hypertrophic cardiomyopathy-Liwen RF™ radio frequency ablation system


    The clinical evidence is encouraging

    The Liwen RF™ radio frequency ablation system has successfully completed the exploratory clinical research of the new technology, and has now officially entered the stage of registered clinical trials (evaluating the prospective, prospective, Multi-center, single-group target value method clinical research), the research is led by Academician Ge Junbo and Academician Zhang Yun, with Professor Liu Liwen as the main investigator, International TCT Chair Professor Martin Leon, CSI Chair Professor Horst Sievert, and Professor Chaim Lotan as the research Consultant, fourteen tertiary hospitals across the country participated in the research and meticulously built the world's top clinical investigator team


    The study has so far successfully enrolled 28 patients.


    Researcher's Message

    Professor Liu Liwen from Xijing Hospital said: Liwen RF™ radio frequency ablation system, the design of adjustable ablation needle can adjust the size of the ablation focus in real time according to the thickness of the myocardium, and can selectively ablate the base, middle and near apex of the ventricular septum, which is effective It makes up for the shortcomings of the previous surgical treatment of obese heart disease, and shows obvious advantages in safety and effectiveness


    Source: Nuocheng Medical

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.